Difference between revisions of "Acute myeloid leukemia, IDH-mutated"
Jump to navigation
Jump to search
m Tag: visualeditor-switched |
m (Added abstract) Tag: visualeditor-switched |
||
Line 37: | Line 37: | ||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
===References=== | ===References=== | ||
− | # ''' | + | # '''Abstract:''' Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan WB, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, & Stone RM. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study. Blood, 132(Suppl 1), 561. [https://doi.org/10.1182/blood-2018-99-110595 Abstract] [https://clinicaltrials.gov/ct2/show/NCT02074839 NCT02074839] |
=IDH1 relapsed or refractory, salvage therapy= | =IDH1 relapsed or refractory, salvage therapy= |
Revision as of 13:39, 6 June 2019
Section editor | |
---|---|
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO mwschoen |
Note: these are biomarker-specific regimens for patients with IDH-mutated AML, please see the main AML page for other regimens.
8 regimens on this page
8 variants on this page
|
IDH1 first-line therapy, older or 'unfit' patients
Ivosidenib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence |
---|---|
DiNardo et al. 2018 (AG120-C-001) | Phase I/II |
Chemotherapy
- Ivosidenib (Tibsovo) 500 mg PO once per day
Continued indefinitely
References
- Abstract: Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan WB, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, & Stone RM. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study. Blood, 132(Suppl 1), 561. Abstract NCT02074839
IDH1 relapsed or refractory, salvage therapy
Ivosidenib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Efficacy |
---|---|---|
DiNardo et al. 2018 (AG120-C-001) | Phase I/II | ORR: 42% |
Chemotherapy
- Ivosidenib (Tibsovo) 500 mg PO once per day
Continued indefinitely
References
- AG120-C-001: DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386-2398. Epub 2018 Jun 2. link to original article contains protocol PubMed
IDH2 Relapsed or refractory, salvage therapy
Enasidenib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Efficacy |
---|---|---|
Stein et al. 2017 (AG-221-C-001) | Phase I/II | ORR: 40% |
This is the dose used in the phase II expansion cohort; enrolled patients were required to have IDH2-mutated advanced myeloid malignancies.
Chemotherapy
- Enasidenib (Idhifa) 100 mg PO once per day
28-day cycles
References
- AG-221-C-001: Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. link to original article contains verified protocol link to PMC article PubMed